Tamoxifen-Based Dimers: Design, Synthesis, Cell Viability Evaluation on Breast Cancer Cells, and Computational...

Area of Science:

• Oncology
• Medicinal Chemistry
• Molecular Biology

Background:

• Tamoxifen resistance is a major obstacle in treating estrogen receptor-positive (ER+) breast cancer.
• Developing novel therapeutic agents is crucial to overcome treatment resistance.

Purpose of the Study:

• To synthesize and evaluate novel tamoxifen-based dimers for antitumor activity.
• To investigate the efficacy and selectivity of (Z,Z)-1 as a potential breast cancer therapeutic.

Main Methods:

• Synthesis of four novel tamoxifen-based dimers.
• In vitro antiproliferative assays using ER+ breast cancer cells (MCF-7), triple-negative cancer cells, and non-cancerous cells.
• Apoptosis induction studies and cell cycle analysis.
• Molecular docking studies with estrogen receptor alpha (ERα).

Main Results:

• (Z,Z)-1 demonstrated significant antiproliferative effects against ER+ cells, outperforming tamoxifen.
• Selective toxicity was observed for (Z,Z)-1 towards cancer cells over normal cells.
• (Z,Z)-1 induced apoptosis via a cell-cycle-independent mechanism, distinct from tamoxifen's G0/G1 arrest.
• Docking studies confirmed strong binding affinity of (Z,Z)-1 to ERα.

Conclusions:

• (Z,Z)-1 is a potent and selective agent against ER+ breast cancer.
• Its distinct mechanism of action and strong ERα binding suggest potential as an alternative to tamoxifen.
• (Z,Z)-1 warrants further investigation for clinical development in ER+ breast cancer treatment.